Suppr超能文献

RB/E2F1作为晚期疾病中癌细胞代谢的主要调节因子。

RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.

作者信息

Mandigo Amy C, Yuan Wei, Xu Kexin, Gallagher Peter, Pang Angel, Guan Yi Fang, Shafi Ayesha A, Thangavel Chellappagounder, Sheehan Beshara, Bogdan Denisa, Paschalis Alec, McCann Jennifer J, Laufer Talya S, Gordon Nicolas, Vasilevskaya Irina A, Dylgjeri Emanuela, Chand Saswati N, Schiewer Matthew J, Domingo-Domenech Josep, Den Robert B, Holst Jeff, McCue Peter A, de Bono Johann S, McNair Christopher, Knudsen Karen E

机构信息

Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.

The Institute of Cancer Research, London, United Kingdom.

出版信息

Cancer Discov. 2021 Sep;11(9):2334-2353. doi: 10.1158/2159-8290.CD-20-1114. Epub 2021 Apr 20.

Abstract

Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss on cell-cycle regulation. Here, isogenic modeling of RB loss identified disease stage-specific rewiring of E2F1 function, providing the first-in-field mapping of the E2F1 cistrome and transcriptome after RB loss across disease progression. Biochemical and functional assessment using both and models identified an unexpected, prominent role for E2F1 in regulation of redox metabolism after RB loss, driving an increase in the synthesis of the antioxidant glutathione, specific to advanced disease. These E2F1-dependent events resulted in protection from reactive oxygen species in response to therapeutic intervention. On balance, these findings reveal novel pathways through which RB loss promotes cancer progression and highlight potentially new nodes of intervention for treating RB-deficient cancers. SIGNIFICANCE: This study identifies stage-specific consequences of RB loss across cancer progression that have a direct impact on tumor response to clinically utilized therapeutics. The study herein is the first to investigate the effect of RB loss on global metabolic regulation and link RB/E2F1 to redox control in multiple advanced diseases..

摘要

视网膜母细胞瘤(RB)肿瘤抑制蛋白的缺失是重编程驱动癌症进展的生物网络的关键步骤,尽管其机制研究主要局限于RB缺失对细胞周期调控的影响。在此,RB缺失的同基因模型确定了E2F1功能在疾病阶段特异性的重新布线,提供了在疾病进展过程中RB缺失后E2F1顺式作用元件组和转录组的首次领域内图谱。使用两种模型进行的生化和功能评估确定了RB缺失后E2F1在氧化还原代谢调控中出人意料的突出作用,这推动了晚期疾病特有的抗氧化剂谷胱甘肽合成增加。这些E2F1依赖性事件导致在治疗干预时免受活性氧的影响。总体而言,这些发现揭示了RB缺失促进癌症进展的新途径,并突出了治疗RB缺陷型癌症潜在的新干预节点。意义:本研究确定了癌症进展过程中RB缺失的阶段特异性后果,这些后果对肿瘤对临床应用治疗的反应有直接影响。本文的研究首次探讨了RB缺失对整体代谢调控的影响,并将RB/E2F1与多种晚期疾病中的氧化还原控制联系起来。

相似文献

8
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.RB 缺陷型癌症中的新型致癌转录因子合作
Cancer Res. 2022 Jan 15;82(2):221-234. doi: 10.1158/0008-5472.CAN-21-1159. Epub 2021 Oct 8.

引用本文的文献

6
Regulation of ferroptosis by transcription factor E2F1.转录因子E2F1对铁死亡的调控
Biochimie. 2025 Jun 25;236:127-137. doi: 10.1016/j.biochi.2025.06.013.

本文引用的文献

2
Understanding of ROS-Inducing Strategy in Anticancer Therapy.理解 ROS 诱导策略在抗癌治疗中的作用。
Oxid Med Cell Longev. 2019 Dec 18;2019:5381692. doi: 10.1155/2019/5381692. eCollection 2019.
9
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.癌症中获得性 CDK4/6 抑制剂耐药导致的 MAPK 依赖。
Clin Cancer Res. 2018 Sep 1;24(17):4201-4214. doi: 10.1158/1078-0432.CCR-18-0410. Epub 2018 May 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验